[Changes of T lymphocyte subsets in BERH-2 hepatoma-bearing rats and effect of different immunotherapies on the tumor].
Peripheral blood and tumor-infiltrating T lymphocyte subsets in BERH-2 hepatoma-bearing rats were investigated by indirect immunofluorescence stain and flow cytometry. Based on the above study, comparison of immunoregulatory action and inhibitory effect on the tumor were also done in vivo among several groups which received IFN, IL-2, 5-FU, combined immunotherapy (CI) or immunochemotherapy (IC), respectively. The results indicated that T lymphocyte subsets in hepatoma-bearing rats would undergo changes which were closely related with tumor growth and metastasis. IC had multiple phased advantages against the tumor, such as improving immunity, eliminating immunosuppression and directly killing the tumor cells. It is a valuable therapeutic regime in hepatoma.
Guo
Y J
YJ
Institute of Hepatobiliary Surgery, Changhai Hospital, Second Military Medical College, Shanghai.
D000818:Animals; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013601:T-Lymphocytes / Q000276:immunology*
D007376:Interleukin-2; D007372:Interferons; D005472:Fluorouracil